Karbox

Oxcarbazepine, the active ingredient in Karbox, is a sodium channel blocker presented as an oral tablet for oral use. It is used to manage partial seizures and generalized tonic‑clonic seizures in patients with epilepsy.

GNH USA supplies Karbox as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Karbox, an oral anticonvulsant, is employed in the treatment of seizure disorders within the epilepsy disease family.

- Partial seizures: reduces the frequency and severity of focal onset seizures. - Generalized tonic‑clonic seizures: helps prevent convulsive episodes that affect the whole brain. - Epilepsy: contributes to overall seizure control as part of a comprehensive management plan.

Oxcarbazepine may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Dizziness: sensation of light‑headedness or unsteadiness. - Drowsiness: increased sleepiness or fatigue. - Headache: mild to moderate cranial pain. - Nausea: upset stomach or urge to vomit. - Double vision: transient visual disturbances. - Fatigue: reduced energy levels.

Serious or Rare Side Effects: - Severe skin reactions: such as Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Hyponatremia: abnormally low blood sodium levels, potentially causing confusion or seizures. - Blood dyscrasias: including agranulocytosis or aplastic anaemia. - Hepatic failure: impaired liver function. - Suicidal ideation: emergence of thoughts of self‑harm. - Blood disorders: thrombocytopenia or leukopenia.

When prescribing or dispensing Karbox, several safety considerations should be observed.

- Renal impairment: assess kidney function and adjust dose if necessary. - Hepatic impairment: monitor liver enzymes and consider dose modification. - Hyponatremia risk: check serum sodium regularly, especially in the elderly. - Pregnancy: safety data are limited; discuss potential risks with a healthcare professional. - Concomitant sodium‑channel blockers: avoid combined use to reduce additive neuro‑toxicity. - Store at ambient temperature: keep below 25 °C, retain in original packaging, and protect from moisture.

Oxcarbazepine can alter the plasma concentrations of several co‑administered medicines.

Major Interactions (Avoid): - Carbamazepine: induces metabolism, reducing oxcarbazepine efficacy. - Strong CYP3A inducers (e.g., rifampin, phenytoin): markedly lower oxcarbazepine levels. - Strong CYP3A inhibitors (e.g., itraconazole, ketoconazole): increase oxcarbazepine exposure and toxicity.

Moderate Interactions (Monitor Closely): - Oral contraceptives: reduced hormonal effectiveness, consider alternative contraception. - NSAIDs: may potentiate hyponatremia, monitor electrolytes. - SSRIs or SNRIs: increased risk of hyponatremia, observe sodium levels. - Antihypertensives: possible additive blood‑pressure lowering effect. - Anticoagulants: monitor INR or PT if used concurrently.